These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 10366253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 7. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
    Koehler R, Bartram CR.
    Klin Padiatr; 2013 May 20; 225 Suppl 1():S40-4. PubMed ID: 23700054
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E.
    Leuk Res; 2009 Jan 20; 33(1):46-53. PubMed ID: 18639340
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of molecular techniques to confirm true re-emergence of the original clone and to track minimal residual disease in a case of late extramedullary relapse of childhood acute lymphoblastic leukemia.
    Valetto A, Anselmi G, Scuderi F, Lanciotti M, Chiesa V, Dini G.
    Haematologica; 2000 Oct 20; 85(10):1102-3. PubMed ID: 11025609
    [No Abstract] [Full Text] [Related]

  • 16. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia.
    Foroni L, Hoffbrand AV.
    Best Pract Res Clin Haematol; 2002 Mar 20; 15(1):71-90. PubMed ID: 11987917
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
    Seyfarth J, Madsen HO, Nyvold C, Ryder LP, Clausen N, Jonmundsson GK, Wesenberg F, Schmiegelow K.
    Med Pediatr Oncol; 2003 Feb 20; 40(2):82-7. PubMed ID: 12461790
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.